Treatment
D-2570 clinical trials
We’re tracking 7 recruiting studies that include D-2570, each written for real people, not researchers, below.
Recruiting studies
- NCT07311200RecruitingPhase 2
Study of D-2570 for active lupus
This trial tests a new oral medication called D-2570 for people with active systemic lupus erythematosus (SLE). It aims to see if the drug can help control lupus symptoms while you continue your current stable treatments.
Linfen, JiangxiAges 18–70 - NCT07625891RecruitingPhase 2
Testing D-2570 for non-segmental vitiligo
This Phase 2 trial tests whether a new drug called D-2570 can help restore skin color in people with non-segmental vitiligo (when white patches appear randomly across the body). The study will track how well the drug works and check if it's safe to use.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT07489885RecruitingPhase 2
Study of D-2570 for moderate to severe plaque psoriasis
This trial tests an experimental drug, D-2570, for people with moderate to severe plaque psoriasis. It aims to see if the medication can safely improve skin symptoms.
Birmingham, AlabamaAges 18–70 - NCT07315061RecruitingPhase 2
Testing D-2570 for active psoriatic arthritis
This trial tests an oral medication, D-2570, for people with active psoriatic arthritis. It aims to see if the drug can reduce joint pain and swelling.
Chengdu, SichuanAges 18–70 - NCT07130604RecruitingPhase 3
Testing a new pill for moderate to severe plaque psoriasis
This trial tests an experimental pill called D-2570 for people with moderate to severe plaque psoriasis. It aims to see if the pill can safely improve skin symptoms like redness, scaling, and thickness.
Beijing, Beijing MunicipalityAges 18–70 - NCT07326813RecruitingPhase 3
Testing D-2570 for moderate to severe plaque psoriasis
This trial tests if a new oral medication called D-2570 can safely and effectively treat moderate to severe plaque psoriasis. It may be an option if your psoriasis covers a large area and has been stable for at least 6 months.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07715149RecruitingPhase 1
D-2570 study for people with and without liver issues
This trial tests how a drug called D-2570 is processed in people with different levels of liver function. It compares people with liver impairment to those with healthy livers to see how the drug moves through the body.
Bengbu, AnhuiAges 18–70
What D-2570 is being studied for
Conditions with recruiting D-2570 studies.
Common questions
- Are there clinical trials studying D-2570?
- Yes. Clin2 currently lists 7 recruiting studies that include D-2570, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a D-2570 trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is D-2570 an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether D-2570 or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.